|Articles|October 1, 2002
QoL up, costs down with experimental LHRH regimen
Orlando, FL-Using serum testosterone levels rather than labelguidelines to re-dose patients on luteinizing hormone-releasing hormone(LHRH) agonist depot therapy can substantially reduce treatment costs andimprove a patient's quality of life, according to researchers at Case WesternReserve University, Cleveland.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5